Skip to main content
SpringerLink
Log in

Targeted Therapy and Prevention of Endometrial Cancer

  • Chapter
  • First Online:
Precision Molecular Pathology of Uterine Cancer

Part of the book series: Molecular Pathology Library ((MPLB,volume 11))

  • 605 Accesses

Abstract

Endometrial (uterine) cancer is a molecularly aberrant disease with over 80% demonstrating a molecular alteration. Primarily, these are in the phosphatidylinositol-3 kinase/protein kinase B (PI3K/AKT) signaling pathway. Given the number of abnormalities present, endometrial cancer has great potential to derive benefit from targeted therapy. However, there are significant unmet needs to maximize the development of targeted therapy in endometrial cancer, including prioritization of agents and pathways and identification and validation of candidate biomarkers to determine mechanisms of response and resistance. Further, as a tumor with a clear precursor lesion and a genetic cause, prevention of endometrial cancer has been explored, although success has been modest. This chapter will review pathways of interest and targeted therapy development in endometrial cancer as well as the current state of endometrial cancer prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, Hopkins PN, Hunt SC. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring). 2009;17(4):796–802. doi:10.1038/oby.2008.610.

    Article  Google Scholar 

  2. Aghajanian C, Filiaci VL, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender D, O’Malley DM, Stuckey A, Rotmensch J, Levine DA, Lankes HA, Moore KN. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. J Clin Oncol. 2015;33(suppl; abstr 5500).

    Google Scholar 

  3. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic oncology group study. J Clin Oncol. 2011;29 (16):2259–65. doi:10.1200/JCO.2010.32.6397 (JCO.2010.32.6397 [pii]).

  4. Alvarez EA, Brady WE, Walker JL, Rotmensch J, Zhou XC, Kendrick JE, Yamada SD, Schilder JM, Cohn DE, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(1):22–7. doi:10.1016/j.ygyno.2012.12.022.

    Article  CAS  PubMed  Google Scholar 

  5. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505. doi:S0140–6736(05)67063-8 [pii] 10.1016/S0140-6736(05)67063-8.

  6. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010;36(6):492–500. doi:10.1016/j.ctrv.2010.02.015 (S0305-7372(10)00035-6 [pii]).

  7. Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011;117(9):1788–99. doi:10.1002/cncr.25738.

    Article  PubMed  Google Scholar 

  8. Ballard-Barbash R, Swanson CA. Body weight: estimation of risk for breast and endometrial cancers. Am J Clin Nutr. 1996;63(3 Suppl):437S–41S.

    CAS  PubMed  Google Scholar 

  9. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Perez-Garcia J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–8. doi:10.1158/1078-0432.CCR-14-1814.

    Article  CAS  PubMed  Google Scholar 

  10. Beining RM, Dennis LK, Smith EM, Dokras A. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol. 2008;18(6):492–9. doi:10.1016/j.annepidem.2007.11.011.

    Article  PubMed  Google Scholar 

  11. Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, Silasi DA, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015;138(1):11–7. doi:10.1016/j.ygyno.2015.04.027.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9(5):1092–99. doi:10.1158/1535-7163.MCT-09-1186 (1535-7163.MCT-09-1186 [pii]).

  13. Bendell J, LoRusso P, Kwak E, Pandya S, Musib L, Jones C, De Crespigny A, Belvin M, McKenzie M, Gates MR, Chan I, Sharpiro G. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GSC-0941: a first-in-human phase Ib study in patients with advanced solid tumors. 2011. AACR meeting abstracts abstract LB-89.

    Google Scholar 

  14. Bender D, Sill MW, Lankes HA, Reyes HD, Darus CJ, Delmore JE, Rotmensch J, Gray HJ, Mannel RS, Schilder JM, Hunter MI, McCourt CK, Samuelson MI, Leslie KK. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015;138(3):507–12. doi:10.1016/j.ygyno.2015.07.018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Beral V, Bull D, Reeves G, Million Women Study C. Endometrial cancer and hormone-replacement therapy in the million women study. Lancet. 2005;365(9470):1543–51. doi:10.1016/S0140-6736(05)66455-0.

  16. Bravi F, Scotti L, Bosetti C, Zucchetto A, Talamini R, Montella M, Greggi S, Pelucchi C, Negri E, Franceschi S, La Vecchia C. Food groups and endometrial cancer risk: a case-control study from Italy. Am J Obstet Gynecol. 2009;200(3):293 e291–7. doi:10.1016/j.ajog.2008.09.015.

  17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423.

    Article  PubMed  Google Scholar 

  18. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol. 2016;116(1):92–8. doi:10.1016/j.ygyno.2009.09.024 (S0090-8258(09)00723-9 [pii]).

  19. Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989;129(6):1120–31.

    Article  CAS  PubMed  Google Scholar 

  20. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev. 2002;13(1):75–85.

    Article  CAS  PubMed  Google Scholar 

  21. Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R, Lopez-Beltran A. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011;7(4):519–41. doi:10.2217/fon.11.25.

    Article  CAS  PubMed  Google Scholar 

  22. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011;1(2):170–85. doi:10.1158/2159-8290.CD-11-0039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358(11):1160–74. doi:10.1056/NEJMra0707704 (358/11/1160 [pii]).

  24. Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(3):538–43. doi:10.1016/j.ygyno.2012.08.020.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Coleman R, Sill M, Thaker PH, De Geest K, Street D, McGuire W, Rotmensch J. A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130(1):e12–3.

    Article  Google Scholar 

  26. Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R, Braly P, Matei D, Morosky A, Dodion PF, Einstein MH, Haluska F. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108(5):1021–6. doi:10.1038/bjc.2013.59.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Correa R, Mackay H, Hirte HW, Morgan R, Welch S, Fleming GF, Wang L, Blattler C, Ivey SP, Oza AM. A phase II study of sunitinib in recurrent or metastastic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J Clin Oncol. 2010;28:15s(suppl; abstr 5038).

    Google Scholar 

  28. Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Chang-Claude J, Boeing H, Schulz M, Benetou V, Trichopoulou A, Trichopoulos D, Palli D, Berrino F, Tumino R, Mattiello A, Vineis P, Quiros JR, Agudo A, Sanchez MJ, Larranaga N, Navarro C, Ardanaz E, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Bingham S, Khaw KT, Key T, Slimani N, Riboli E, Kaaks R. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007;120(12):2656–64. doi:10.1002/ijc.22578.

    Article  CAS  PubMed  Google Scholar 

  29. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR. Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA. 2002;287(19):2559–62.

    Article  CAS  PubMed  Google Scholar 

  30. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008;214(3):559–67. doi:10.1002/jcp.21260.

  31. Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10(8):1192–9. doi:10.4161/cc.10.8.15273 ([pii]).

  32. Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonzalez-Martin A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016;142(1):62–9. doi:10.1016/j.ygyno.2016.04.019.

  33. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest. 2010;120(8):2858–66. doi:10.1172/JCI37539 (37539 [pii]).

  34. Dizon DS, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135(3):441–5. doi:10.1016/j.ygyno.2014.10.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010;70(6):2264–73. doi:10.1158/0008-5472.CAN-09-1577.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Duffy SR, Distler W, Howell A, Cuzick J, Baum M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol. 2009;200(1):80 e81–7. doi:10.1016/j.ajog.2008.07.062.

  37. Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res. 1994;54(6):1604–7.

    CAS  PubMed  Google Scholar 

  38. Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, Kemsley K, Cantarini MV, Morris C, Kirkwood JM. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol. 2008;26:Suppl; abstr 9033.

    Google Scholar 

  39. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105(25):8713–7. doi:10.1073/pnas.0803379105 (0803379105 [pii]).

  40. Dutt A, Salvesen HB, Greulich H, Sellers WR, Beroukhim R, Meyerson M. Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer. 2009;101(7):1218–9 (author reply 1220–11). doi:10.1038/sj.bjc.6605301 (6605301 [pii]).

  41. Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977;59(4):1055–60.

    Article  CAS  PubMed  Google Scholar 

  42. Engel JB, Honig A, Schonhals T, Weidler C, Hausler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. Eur J Obstet Gynecol Reprod Biol. 2008;141(1):64–9. doi:10.1016/j.ejogrb.2008.06.007.

    Article  CAS  PubMed  Google Scholar 

  43. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–6. doi:10.1038/nm.1890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14(10):2895–9. doi:10.1158/1078-0432.CCR-07-2248 (14/10/2895 [pii]).

  45. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5. doi:10.1136/bmj.38415.708634.F7 (bmj.38415.708634.F7 [pii]).

  46. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM, Australian Ovarian Cancer Study G, Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control: CCC. 2010;21(12):2303–8. doi:10.1007/s10552-010-9658-7.

  47. Felix AS, Gaudet MM, La Vecchia C, Nagle CM, Shu XO, Weiderpass E, Adami HO, Beresford S, Bernstein L, Chen C, Cook LS, De Vivo I, Doherty JA, Friedenreich CM, Gapstur SM, Hill D, Horn-Ross PL, Lacey JV, Levi F, Liang X, Lu L, Magliocco A, McCann SE, Negri E, Olson SH, Palmer JR, Patel AV, Petruzella S, Prescott J, Risch HA, Rosenberg L, Sherman ME, Spurdle AB, Webb PM, Wise LA, Xiang YB, Xu W, Yang HP, Yu H, Zeleniuch-Jacquotte A, Brinton LA. Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2015;136(5):E410–22. doi:10.1002/ijc.29229.

    Article  CAS  PubMed  Google Scholar 

  48. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  PubMed  Google Scholar 

  49. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14. doi:10.1056/NEJMoa1203421.

    Article  CAS  PubMed  Google Scholar 

  50. Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, Makker V, Burke JJ 2nd, Zweizig SL, Van Le L, Hanjani P, Downey G, Walker JL, Reyes HD, Leslie KK. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132(3):585–92. doi:10.1016/j.ygyno.2014.01.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;116(1):15–20. doi:10.1016/j.ygyno.2009.09.025 (S0090-8258(09)00724-0 [pii]).

  52. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34. doi:10.1056/NEJMoa0900212 (NEJMoa0900212 [pii]).

  53. Foster P, Yamaguchi K, Hsu PP, Qian F, Du X, Wu J, Won KA, Yu P, Jaeger CT, Zhang W, Marlowe CK, Keast P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Engell K, Bentzien F, Lam ST, Dale S, Yturralde O, Matthews DJ, Lamb P, Laird AD. The selective PI3K inhibitor XL147 (SAR245408) inhibits tumor growth and survival and potentiates the activity of chemotherapeutic agents in preclinical tumor models. Mol Cancer Ther. 2015;14(4):931–40. doi:10.1158/1535-7163.MCT-14-0833.

    Article  CAS  PubMed  Google Scholar 

  54. Friberg E, Orsini N, Mantzoros CS, Wolk A. Alcohol intake and endometrial cancer risk: a meta-analysis of prospective studies. Br J Cancer. 2010;103(1):127–31. doi:10.1038/sj.bjc.6605698.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14(2):342–6. doi:10.1158/1078-0432.CCR-07-4790 (14/2/342 [pii]).

  56. Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Courneya KS, Magliocco AM, Yasui Y, Cook LS. Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2384–95. doi:10.1158/1055-9965.EPI-11-0715.

    Article  CAS  PubMed  Google Scholar 

  57. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014;13(5):1117–29. doi:10.1158/1535-7163.MCT-13-0865.

    Article  CAS  PubMed  Google Scholar 

  58. Gavaler JS, Van Thiel DH. Hormonal status of postmenopausal women with alcohol-induced cirrhosis: further findings and a review of the literature. Hepatology. 1992;16(2):312–9.

    Article  CAS  PubMed  Google Scholar 

  59. Gien LT, Mackay HJ. The emerging role of PARP inhibitors in the treatment of epithelial ovarian cancer. J Oncol. 2010. doi:10.1155/2010/151750 (ID 151750).

  60. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):3–9. doi:10.1016/j.ygyno.2007.09.007 (S0090-8258(07)00727-5 [pii]).

  61. Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies. J Nucl Med. 2015;56(12):1828–35. doi:10.2967/jnumed.115.156505.

    Article  CAS  PubMed  Google Scholar 

  62. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87(17):1297–302.

    Article  CAS  PubMed  Google Scholar 

  63. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8(11):1439–52. doi:10.1158/1541-7786.MCR-10-0168.

    Article  CAS  PubMed  Google Scholar 

  64. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res. 2006;12(20 Pt 1):5932–5. doi:10.1158/1078-0432.CCR-06-1375 (12/20/5932 [pii]).

  65. Heist RS, Gandhi L, Shapiro G, Rizvi NA, Burris HA, Bendell JC, Baselga J, Yerganian SB, Hsu K, Ogden J, Vincent L, von Richter O, Locatelli G, Asatiani E, Infante JR. Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: results of a phase Ib dose-escalation trial. J Clin Oncol. 2013;31(suppl; abstr 2530).

    Google Scholar 

  66. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr. 2007;1(3):133–6. doi:4978 ([pii]).

    Google Scholar 

  67. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004. doi:10.1038/nrd1902 (nrd1902 [pii]).

  68. Henretta MS, Copeland AR, Kelley SL, Hallowell PT, Modesitt SC. Perceptions of obesity and cancer risk in female bariatric surgery candidates: highlighting the need for physician action for unsuspectingly obese and high risk patients. Gynecol Oncol. 2014;133(1):73–7. doi:10.1016/j.ygyno.2014.01.016.

    Article  PubMed  Google Scholar 

  69. Heudel P-E, Fabbro M, Roemer-Becuwe C, Treilleux I, Kaminsky M-C, Arnaud A, Joly F, Forestier SR, Herve R, Ray-Coquard I. Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study. J Clin Oncol. 2015;33(Suppl; abstr 5588).

    Google Scholar 

  70. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27. doi:10.1200/JCO.2005.06.081 (JCO.2005.06.081 [pii]).

  71. Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, Rajashankar KR, Wang B, Nikolov DB. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep. 2009;10(7):722–8. doi:10.1038/embor.2009.91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–67. doi:10.1158/1535-7163.MCT-09-1012.

    Article  CAS  PubMed  Google Scholar 

  73. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol. 2001;80(2):181–8. doi:10.1006/gyno.2000.6056S0090-8258(00)96056-6 ([pii]).

  74. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 2009;15(14):4649–64. doi:10.1158/1078-0432.CCR-09-0317.

    Article  CAS  PubMed  Google Scholar 

  75. Howitt BE, Sholl LM, Ritterhouse L, Watkins JC, Rodig SJ, Strickland K, D’Andrea AD, Matulonis U, Konstantinopoulos P. Association of POLE-mutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1. J Clin Oncol. 2015;33(suppl; abstr 5511).

    Google Scholar 

  76. Hyman DM, Smyth L, Bedard PL, Oza A, Dean E, Armstrong A, Lima J, Bando H, Kabos P, Perez-Fidalgo JA, Moore KM, Westin SN, You B, Chandarlapaty S, Alland L, Ambrose H, Foxley A, Lindemann J, Pass M, Rugman P, Salim S, Schiavon G, Tamura K, Baselga J, Banerji U. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 D17K mutation positive advanced solid tumors. In: AACR-NCI-EORTC International conference molecular targets and cancer therapeutics, Boston, MA; 2016.

    Google Scholar 

  77. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, Lu KH. Another surprise from metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy. Mol Cancer Ther. 2013;12(12):2847–56. doi:10.1158/1535-7163.MCT-13-0439.

    Article  CAS  PubMed  Google Scholar 

  78. Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1):143–50. doi:10.1158/0008-5472.CAN-07-6656.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009;15(16):5267–73. doi:10.1158/1078-0432.CCR-09-0888 (1078-0432.CCR-09-0888 [pii]).

  80. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369–80. doi:10.1016/j.ejca.2010.06.012.

    Article  CAS  PubMed  Google Scholar 

  81. Juric D, Soria JC, Sharma S, Banerji U, Azaro A, Desai J, Ringeisen FP, Kaag A, Radhakrishnan R, Hourcade-Potelleret F, Maacke H, Ahnert JR. A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. J Clin Oncol. 2014;32:5s (suppl; abstr 9051).

    Google Scholar 

  82. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531–43.

    CAS  PubMed  Google Scholar 

  83. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer. 2009;115(12):2684–92. doi:10.1002/cncr.24335.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13(24):7487–95. doi:10.1158/1078-0432.CCR-07-1017 (13/24/7487 [pii]).

  85. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.

    Article  PubMed  CAS  Google Scholar 

  86. Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 2006;119(6):1316–21. doi:10.1002/ijc.21991.

    Article  CAS  PubMed  Google Scholar 

  87. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt T Jr, Watring WG, Rosenshein NB, Lewis JL Jr, Schottenfeld D, Engle RL Jr. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med. 1980;303(18):1045–7. doi:10.1056/NEJM198010303031807.

    Article  CAS  PubMed  Google Scholar 

  88. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994;53(1):84–92. doi:10.1006/gyno.1994.1092 (S0090-8258(84)71092-4 [pii]).

  89. Kikawa KD, Vidale DR, Van Etten RL, Kinch MS. Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem. 2002;277(42):39274–9. doi:10.1074/jbc.M207127200.

    Article  CAS  PubMed  Google Scholar 

  90. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs. 2010;19(3):415–25. doi:10.1517/13543781003592097.

  91. Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncol. 2015;16(6):686–94. doi:10.1016/S1470-2045(15)70159-2.

    Article  CAS  PubMed  Google Scholar 

  92. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10(5):1706–16.

    Article  CAS  PubMed  Google Scholar 

  93. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ, Horii A. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997;17(2):143–4. doi:10.1038/ng1097-143.

    Article  CAS  PubMed  Google Scholar 

  94. Konstantinopoulos P, Makker V, Barry WT, Liu J, Horowitz NS, Birrer MJ, Doyle LA, Berlin ST, Whalen C, Van Hummelen P, Coleman RL, Aghajanian C, Mills GB, Matulonis U, Westin SN, Myers AP. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 5515).

    Google Scholar 

  95. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 2002;94(9):2369–79. doi:10.1002/cncr.10498.

    Article  CAS  PubMed  Google Scholar 

  96. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–58. doi:10.1001/jama.290.16.2149290/16/2149 [pii].

  97. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Lee CN, Cheng WF, Chen CA, Chu JS, Hsieh CY, Hsieh FJ. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet Gynecol. 2000;96(4):615–21.

    CAS  PubMed  Google Scholar 

  99. Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(3):486–94. doi:10.1016/j.ygyno.2013.02.019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127(2):345–50. doi:10.1016/j.ygyno.2012.07.127.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Levi F, Franceschi S, Negri E, La Vecchia C. Dietary factors and the risk of endometrial cancer. Cancer. 1993;71(11):3575–81.

    Article  CAS  PubMed  Google Scholar 

  102. Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review). Oncol Rep. 2009;22(4):671–81.

    CAS  PubMed  Google Scholar 

  103. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes. 2011. doi:10.1111/j.1753-0407.2011.00119.x

  104. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 2012;22(11):2120–9. doi:10.1101/gr.137596.112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296(12):1507–17. doi:10.1001/jama.296.12.1507.

    Article  CAS  PubMed  Google Scholar 

  106. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006;100(1):101–6. doi:10.1016/j.ygyno.2005.07.124.

    Article  CAS  PubMed  Google Scholar 

  107. Lorusso D, Ferrandina G, Colombo N, Pignata S, Salutari V, Maltese G, Pisano C, Lapresa M, Savarese A, Tagliaferri P, Sorio R, Cinieri S, Breda E, Sabbatini R, Lepori S, Conte C, Cecere SC, Raspagliesi F, Scambia G. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J Clin Oncol. 2015;33(suppl; abstr 5502).

    Google Scholar 

  108. Lu Y, Wang SS, Sullivan-Halley J, Chang ET, Clarke CA, Henderson KD, Ma H, Duan L, Lacey JV Jr, Deapen D, Bernstein L. Oral contraceptives, menopausal hormone therapy use and risk of B-cell non-Hodgkin lymphoma in the California Teachers Study. Int J Cancer. 2011;129(4):974–82. doi:10.1002/ijc.25730.

    Article  CAS  PubMed  Google Scholar 

  109. Lynch TJ. The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer. Clin Adv Hematol Oncol. 2004;2(12):786–7.

    PubMed  Google Scholar 

  110. Mackay HJ, Eisenhauer EA, Kamel-Reid S, Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA, Salvesen HB, Tu D, Oza AM. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer. 2013;. doi:10.1002/cncr.28414.

    PubMed  Google Scholar 

  111. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev. 2005;31(8):603–17. doi:10.1016/j.ctrv.2005.09.006 (S0305-7372(05)00174-X [pii]).

  112. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–28. doi:10.1158/1535-7163.MCT-11-0474.

    Article  CAS  PubMed  Google Scholar 

  113. Makker V, Recio FO, Ma L, Matulonis U, Lauchle JO, Parmar H, Gilbert H, Wang Y, Koeppen H, Spoerke JM, Lackner M, Aghajanian C. Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results. J Clin Oncol. 2014;32:5s (suppl; abstr 5513).

    Google Scholar 

  114. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7(8):497–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13(10):2890–6. doi:10.1158/1078-0432.CCR-06-3043 (13/10/2890 [pii]).

  116. Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–53. doi:10.1016/j.ygyno.2014.12.019.

    Article  CAS  PubMed  Google Scholar 

  117. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12(21):6373–8. doi:10.1158/1078-0432.CCR-06-0912 (12/21/6373 [pii]).

  118. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007;105(2):508–16. doi:10.1016/j.ygyno.2007.01.019 (S0090-8258(07)00034-0 [pii]).

  119. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009;1(6–7):315–22. doi:10.1002/emmm.200900041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Messersmith WA, Falchook GS, Fecher LA, Gordon MS, Vogelzang NJ, DeMarini DJ, Peddareddigari VG, Xu Y, Bendell JC, Infante JR. Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212. J Clin Oncol. 2011;29(suppl 4: abstr 246).

    Google Scholar 

  121. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. Int J Gynecol Cancer. 2014;24(4):713–7. doi:10.1097/IGC.0000000000000118.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen ML, Wang B. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009;16(1):9–20. doi:10.1016/j.ccr.2009.04.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Miller DS, Filiaci VJ, Fleming G, Mannel R, Cohn DE, Matsumoto T, Tewari K, DiSilvestro PA, Pearl M, Zaino RJ. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:771.

    Article  Google Scholar 

  125. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res. 2010;16(11):3044–56. doi:10.1158/1078-0432.CCR-09-3368 (1078-0432.CCR-09-3368 [pii]).

  126. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283(2):125–34. doi:10.1016/j.canlet.2009.01.022 (S0304-3835(09)00054-8 [pii]).

  127. Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103(7):933–8. doi:10.1038/sj.bjc.6605902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: an NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015;138(3):513–8. doi:10.1016/j.ygyno.2015.07.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Morisset AS, Blouin K, Tchernof A. Impact of diet and adiposity on circulating levels of sex hormone-binding globulin and androgens. Nutr Rev. 2008;66(9):506–16. doi:10.1111/j.1753-4887.2008.00083.x.

    Article  PubMed  Google Scholar 

  130. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376–85. doi:10.1200/JCO.2005.03.4827.

    Article  CAS  PubMed  Google Scholar 

  131. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010;17(4):R263–71. doi:10.1677/ERC-10-0076.

    Article  CAS  PubMed  Google Scholar 

  132. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924–30.

    Article  CAS  PubMed  Google Scholar 

  133. Myers AP, Broaddus R, Makker V, Konstantinopoulos P, Drapkin R, Horowitz NS, Liu J, Van Hummelen P, Meric-Bernstam F, Birrer MJ, Doyle A, Coleman RL, Aghajanian C, Mills GB, Cantley L, Matulonis UA, Westin SN. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. J Clin Oncol. 2013;31(suppl; abstr 5524).

    Google Scholar 

  134. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.

    Article  CAS  PubMed  Google Scholar 

  135. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, Wade JL 3rd, Agamah E, Vokes EE, Fleming GF. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117(1):37–40. doi:10.1016/j.ygyno.2010.01.013.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16. doi:10.1016/j.gene.2005.10.018 (S0378-1119(05)00634-7 [pii]).

  137. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6(9):519–27. doi:10.1038/nrclinonc.2009.111 (nrclinonc.2009.111 [pii]).

  138. Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol. 2006;4(6):459–68.

    PubMed  Google Scholar 

  139. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65(23):10669–73. doi:10.1158/0008-5472.CAN-05-2620 (65/23/10669 [pii]).

  140. Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Morgan MA, Mehnert JM, Aung KL, Carrigan M, Saraf S, Chen M, Soria J-C. Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2016;34(suppl; abstr 5581).

    Google Scholar 

  141. Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, Hansen C, Dancey J, Eisenhauer E. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer–NCIC IND 160. J Clin Oncol. 2006;24(18S):3003.

    Google Scholar 

  142. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278–85. doi:10.1200/JCO.2010.34.1578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Oza AM, Pignata S, Poveda A, McCormack M, Clamp A, Schwartz B, Cheng J, Li X, Campbell K, Dodion P, Haluska FG. Randomized phase ii trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33(31):3576–82. doi:10.1200/JCO.2014.58.8871.

    Article  CAS  PubMed  Google Scholar 

  144. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–25. doi:10.1200/JCO.2007.15.8808 (JCO.2007.15.8808 [pii]).

  145. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500–8. doi:10.1158/0008-5472.CAN-05-2925 (66/3/1500 [pii]).

  146. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992;257(5078):1955–7.

    Article  CAS  PubMed  Google Scholar 

  147. Patel AV, Feigelson HS, Talbot JT, McCullough ML, Rodriguez C, Patel RC, Thun MJ, Calle EE. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008;123(8):1877–82. doi:10.1002/ijc.23716.

  148. Patel SP, Lazar AJ, Mahoney S, Vaughn C, Gonzalez N, Papadopoulos NE, Liu P, Infante JR, LoRusso P, Kim KB. Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. In: 2010 ASCO molecular markers. 2010.

    Google Scholar 

  149. Pena CE, Jeffers M, Genvresse I, Appleman LJ, Ramanathan RK, Patnaik A. Biomarker analysis from a Phase I study of copanlisib with expansion cohorts in solid tumors with and without PIK3CA mutations and NHL. J Clin Oncol. 2016;33(Suppl; abstr 2548).

    Google Scholar 

  150. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105(21):1607–16. doi:10.1093/jnci/djt277.

    Article  CAS  PubMed  Google Scholar 

  151. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26(50):7158–62. doi:10.1038/sj.onc.1210529 (1210529 [pii] ).

  152. Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135(1):38–43. doi:10.1016/j.ygyno.2014.07.083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol. 2014;7:53. doi:10.1186/s13045-014-0053-9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  154. Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein GR, Richards DA, Renshaw FG, Rajogopaian P, Kelly A, Pena CE, Mross KB. A phase 1b trial of PI3K inhibitor copanlisib (BAY 80–6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 2588).

    Google Scholar 

  155. Ray-Coquard I, Favier L, Weber B, Roemer-Becuwe C, Bougnoux P, Fabbro M, Floquet A, Joly F, Plantade A, Paraiso D, Pujade-Lauraine E. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108(9):1771–7. doi:10.1038/bjc.2013.183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi:10.1136/bmj.39367.495995.AE.

  157. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.

    Article  PubMed  Google Scholar 

  158. Rinaldi S, Peeters PH, Bezemer ID, Dossus L, Biessy C, Sacerdote C, Berrino F, Panico S, Palli D, Tumino R, Khaw KT, Bingham S, Allen NE, Key T, Jensen MK, Overvad K, Olsen A, Tjonneland A, Amiano P, Ardanaz E, Agudo A, Martinez-Garcia C, Quiros JR, Tormo MJ, Nagel G, Linseisen J, Boeing H, Schulz M, Grobbee DE, Bueno-de-Mesquita HB, Koliva M, Kyriazi G, Thrichopoulou A, Boutron-Ruault MC, Clavel-Chapelon F, Ferrari P, Slimani N, Saracci R, Riboli E, Kaaks R. Relationship of alcohol intake and sex steroid concentrations in blood in pre- and post-menopausal women: the European Prospective Investigation into Cancer and Nutrition. Cancer Causes Control: CCC. 2006;17(8):1033–43. doi:10.1007/s10552-006-0041-7.

    Article  CAS  PubMed  Google Scholar 

  159. Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin Cancer Res. 2011;17(10):3500–6. doi:10.1158/1078-0432.CCR-10-2102 (1078-0432.CCR-10-2102 [pii]).

  160. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol. 2002;20(15):3302–16.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Sainson RC, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11(1):41–51. doi:10.1007/s10456-008-9098-0.

    Article  CAS  PubMed  Google Scholar 

  162. Salvesen HB, Kumar R, Stefansson I, Angelini S, MacDonald N, Smeds J, Jacobs IJ, Hemminki K, Das S, Akslen LA. Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer. 2005;115(6):930–4. doi:10.1002/ijc.20702.

    Article  CAS  PubMed  Google Scholar 

  163. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.1096502 (1096502 [pii]).

  164. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O’Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8(5):1271–9.

    CAS  PubMed  Google Scholar 

  165. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53(8):1906–10.

    CAS  PubMed  Google Scholar 

  166. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354(3):261–9. doi:10.1056/NEJMoa052627.

    Article  CAS  PubMed  Google Scholar 

  167. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst. 2004;96(21):1635–8. doi:10.1093/jnci/djh291.

    Article  PubMed  Google Scholar 

  168. Schuler KM, Rambally BS, DiFurio MJ, Sampey BP, Gehrig PA, Makowski L, Bae-Jump VL. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer. Cancer Med. 2015;4(2):161–73. doi:10.1002/cam4.353.

    Article  CAS  PubMed  Google Scholar 

  169. Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 2003;31(17):4959–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, Wenham RM. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res. 2012;18(19):5489–98. doi:10.1158/1078-0432.CCR-12-0507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Semczuk A, Berbec H, Kostuch M, Cybulski M, Wojcierowski J, Baranowski W. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients’ outcome. J Cancer Res Clin Oncol. 1998;124(12):695–700.

    Article  CAS  PubMed  Google Scholar 

  172. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, van den Brandt PA, van de Vijver K, Thompson PJ, Australian National Endometrial Cancer Study G, Strom BL, Spurdle AB, Soslow RA, Shu XO, Schairer C, Sacerdote C, Rohan TE, Robien K, Risch HA, Ricceri F, Rebbeck TR, Rastogi R, Prescott J, Polidoro S, Park Y, Olson SH, Moysich KB, Miller AB, McCullough ML, Matsuno RK, Magliocco AM, Lurie G, Lu L, Lissowska J, Liang X, Lacey JV Jr, Kolonel LN, Henderson BE, Hankinson SE, Hakansson N, Goodman MT, Gaudet MM, Garcia-Closas M, Friedenreich CM, Freudenheim JL, Doherty J, De Vivo I, Courneya KS, Cook LS, Chen C, Cerhan JR, Cai H, Brinton LA, Bernstein L, Anderson KE, Anton-Culver H, Schouten LJ, Horn-Ross PL. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18. doi:10.1200/JCO.2012.48.2596.

  173. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(1):233–45. doi:10.1158/1078-0432.CCR-13-1777.

    Article  CAS  PubMed  Google Scholar 

  174. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih Ie M, Uray IP, Wu X, Brown PH, Shen X, Mills GB, Peng G. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 2015;5(7):752–67. doi:10.1158/2159-8290.CD-14-0849.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Shi Q, Li J, Li M, Wu J, Yao Q, Xing A. The role of levonorgestrel-releasing intrauterine system for endometrial protection in women with breast cancer taking tamoxifen. Eur J Gynaecol Oncol. 2014;35(5):492–8.

    Google Scholar 

  176. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005;4(10):1533–40. doi:10.1158/1535-7163.MCT-05-0068.

    Article  CAS  PubMed  Google Scholar 

  177. Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, Nei T, Kawana K, Kuramoto H, Aburatani H, Yano T, Taketani Y. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer. 2009;101(1):145–8. doi:10.1038/sj.bjc.6605109 (6605109 [pii]).

  178. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66 (1):7–30. doi:10.3322/caac.21332.

  179. Simpson ER, Mendelson CR. Effect of aging and obesity on aromatase activity of human adipose cells. Am J Clin Nutr. 1987;45(1 Suppl):290–5.

    CAS  PubMed  Google Scholar 

  180. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects S. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52. doi:10.1056/NEJMoa066254.

    Article  PubMed  Google Scholar 

  181. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, Lu KH, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33(8):930–6. doi:10.1200/JCO.2014.58.3401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126–32. doi:10.1200/JCO.2004.11.154 (22/15/3126 [pii]).

  183. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010a. doi:10.1002/cncr.25515

  184. Slomovitz BM, Schmeler K, Miller DS, Lu K, Ramirez PT, Caputo T, Coleman R, Burke T, Gershenson DM, Wolf J. Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer. Gynecol Oncol. 2010b;166(suppl; abstr 13).

    Google Scholar 

  185. Smith EL, Zamarin D, Lesokhin AM. Harnessing the immune system for cancer therapy. Curr Opin Oncol. 2014;26(6):600–7. doi:10.1097/CCO.0000000000000128.

    Article  CAS  PubMed  Google Scholar 

  186. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999;34(2):320–5.

    Article  CAS  PubMed  Google Scholar 

  187. Soliman PT, Bassett RL Jr, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, Gershenson DM, Lu KH. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol. 2008;112(4):835–42. doi:10.1097/AOG.0b013e318187d022.

    Article  PubMed  Google Scholar 

  188. Soliman PT, Broaddus R, Westin SN, Iglesias DA, Burzawa JK, Zhang Q, Munsell MF, Schmandt R, Ramondetta LM, Lu KH. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: a window of opportunity study. J Clin Oncol. 2014;32:5s (suppl; abstr 5510).

    Google Scholar 

  189. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96. doi:10.1038/nrm3330.

    CAS  PubMed  Google Scholar 

  190. Stanford JL, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Hoover RN. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer. 1993;54(2):243–8.

    Article  CAS  PubMed  Google Scholar 

  191. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006;12(5):1398–401. doi:10.1158/1078-0432.CCR-05-2692.

    Article  CAS  PubMed  Google Scholar 

  192. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2015;21(4):739–48. doi:10.1158/1078-0432.CCR-14-1901.

    Article  CAS  PubMed  Google Scholar 

  193. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J, Ray-Coquard I. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol. 2013;8(4):243–51. doi:10.1007/s11523-012-0242-9.

    Article  PubMed  Google Scholar 

  195. Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–9. doi:10.1016/j.ygyno.2014.06.033.

    Article  CAS  PubMed  Google Scholar 

  196. Van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015;21(14):3347–55. doi:10.1158/1078-0432.CCR-15-0057.

  197. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O’Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011;10(12):2426–36. doi:10.1158/1535-7163.MCT-11-0446.

    Article  CAS  PubMed  Google Scholar 

  198. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol. 2010;3(1):1–12.

    Article  PubMed  PubMed Central  Google Scholar 

  199. Ward KK, Roncancio AM, Shah NR, Davis MA, Saenz CC, McHale MT, Plaxe SC. Bariatric surgery decreases the risk of uterine malignancy. Gynecol Oncol. 2014;133(1):63–6. doi:10.1016/j.ygyno.2013.11.012.

    Article  PubMed  Google Scholar 

  200. Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med. 2011;52(4):497–500. doi:10.2967/jnumed.111.089623 (jnumed.111.089623 [pii]).

  201. Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol. 2013;3:290. doi:10.3389/fonc.2013.00290.

    Article  PubMed  PubMed Central  Google Scholar 

  202. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control: CCC. 2000;11(2):185–92.

    Article  CAS  PubMed  Google Scholar 

  203. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980;302(10):551–4. doi:10.1056/NEJM198003063021004.

    Article  CAS  PubMed  Google Scholar 

  204. Westin SN, Broaddus RR. Personalized therapy in endometrial cancer: challenges and opportunities. Cancer Biol Ther. 2012;13(1):1–13. doi:10.4161/cbt.13.1.18438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. Mol Oncol. 2015. doi:10.1016/j.molonc.2015.04.014.

  206. Westin SN, Sill M, Coleman RL, Waggoner SE, Moore KN, Mathews CA, Jain A, Modesitt SC, Schilder R, Aghajanian C. Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent or persistent endometrial cancer: a NRG Oncology Gynecologic Oncology Group study. In: Society of gynecologic oncology, San Diego, California. 2016.

    Google Scholar 

  207. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol. 2010. doi:10.1016/j.jsbmb.2010.12.006 (S0960–0760(10)00380-8 [pii]).

  208. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242–8. doi:10.1038/35025215.

    Article  CAS  PubMed  Google Scholar 

  209. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269–73. doi:10.1158/0008-5472.CAN-06-1500 (0008-5472.CAN-06-1500 [pii]).

  210. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003;95(23):1797–800.

    Article  PubMed  Google Scholar 

  211. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, Lu KH. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am J Obstet Gynecol. 2013;209(1):24 e21–24 e12. doi:10.1016/j.ajog.2013.03.008.

  212. Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu Y, Zhu Y, Feng Y. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer. 2011;21(2):213–21. doi:10.1097/IGC.0b013e318207dac7 (00009577-201102000-00005 [pii]).

  213. Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, Zhu H, Wang B. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121(6):501–8 e503. doi:10.1016/j.amjmed.2008.01.044.

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Kinan Hospital, Minamimurogun, Mie, Japan

    Takaya Shiozaki

  2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Shannon N. Westin

Authors
  1. Takaya Shiozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shannon N. Westin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shannon N. Westin .

Editor information

Editors and Affiliations

  1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA

    Michael T. Deavers

  2. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA

    Donna M. Coffey

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shiozaki, T., Westin, S.N. (2017). Targeted Therapy and Prevention of Endometrial Cancer. In: Deavers, M., Coffey, D. (eds) Precision Molecular Pathology of Uterine Cancer. Molecular Pathology Library, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-319-57985-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-57985-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-57983-2

  • Online ISBN: 978-3-319-57985-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation